Literature DB >> 9608401

Mild cognitive impairment and risk of mortality in HIV-1 infection.

F L Wilkie1, K Goodkin, C Eisdorfer, D Feaster, R Morgan, M A Fletcher, N Blaney, M Baum, J Szapocznik.   

Abstract

HIV-1-associated cognitive impairment has only been preliminarily investigated for associations with mortality. The authors examined 119 HIV-1-positive homosexual men (asymptomatic: n = 96; early symptomatic: n = 23). At follow-up (to 3.5 years), there were 105 survivors and 14 nonsurvivors. Those at the 25th percentile in response speeds and in long-term memory retrieval accuracy were at 6.4 (P < 0.02) and 3.5 (P < 0.05) times increased mortality risk, respectively, of those at the 75th percentile--independent of baseline CDC clinical stage, CD4 cell count, hemoglobin level, antiretroviral and prophylactic medication use, and sociodemographics. Cognitive impairment should be identified early--for maximization of both functional status and survival time.

Entities:  

Mesh:

Year:  1998        PMID: 9608401     DOI: 10.1176/jnp.10.2.125

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  23 in total

Review 1.  Neuropsychiatric Aspects of Infectious Diseases: An Update.

Authors:  Sahil Munjal; Stephen J Ferrando; Zachary Freyberg
Journal:  Crit Care Clin       Date:  2017-07       Impact factor: 3.598

Review 2.  Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action.

Authors:  Erica Weber; Kaitlin Blackstone; Steven Paul Woods
Journal:  Neuropsychol Rev       Date:  2013-02-16       Impact factor: 7.444

3.  No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.

Authors:  Edwina J Wright; Birgit Grund; Kevin R Robertson; Lucette Cysique; Bruce J Brew; Gary L Collins; Mollie Poehlman-Roediger; Michael J Vjecha; Augusto César Penalva de Oliveira; Barbara Standridge; Cate Carey; Anchalee Avihingsanon; Eric Florence; Jens D Lundgren; Alejandro Arenas-Pinto; Nicolas J Mueller; Alan Winston; Moses S Nsubuga; Luxshimi Lal; Richard W Price
Journal:  AIDS       Date:  2018-05-15       Impact factor: 4.177

4.  The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment.

Authors:  María J Marquine; Anya Umlauf; Alexandra S Rooney; Pariya L Fazeli; Ben D Gouaux; Steven Paul Woods; Scott L Letendre; Ronald J Ellis; Igor Grant; David J Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

5.  CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Authors:  T J Barber; A Imaz; M Boffito; J Niubó; A Pozniak; R Fortuny; J Alonso; N Davies; S Mandalia; D Podzamczer; B Gazzard
Journal:  J Neurovirol       Date:  2017-12-26       Impact factor: 2.643

6.  Impaired Neurocognitive Performance and Mortality in HIV: Assessing the Prognostic Value of the HIV-Dementia Scale.

Authors:  Nikhil Banerjee; Roger C McIntosh; Gail Ironson
Journal:  AIDS Behav       Date:  2019-12

7.  HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.

Authors:  Beau M Ances; David B Clifford
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

8.  Characterization and sociocultural predictors of neuropsychological test performance in HIV+ Hispanic individuals.

Authors:  Monica Rivera Mindt; Desiree Byrd; Elizabeth L Ryan; Reuben Robbins; Jennifer Monzones; Alyssa Arentoft; Kaori Kubo Germano; Debra E Henniger; Susan Morgello
Journal:  Cultur Divers Ethnic Minor Psychol       Date:  2008-10

Review 9.  Update on HIV dementia and HIV-associated neurocognitive disorders.

Authors:  Bruce J Brew; Phillip Chan
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 10.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.